PORTLAND, Ore., July 19 /PRNewswire/ -- UCB, Inc. announced today that
it is joining forces with the Northwest Chapter of the Crohn's and Colitis
Foundation (CCFA) to raise funds that will support finding a cure for
Crohn's (CD), a chronic, debilitating, irritable bowel disease. UCB,
founders of www.CrohnsandMe.com -- a dynamic Web site focused on helping
people thoroughly understand Crohn's disease and live with it every day --
will be the Platinum Sponsor for a Pearl Jam benefit concert on July 20 in
In 2002, Pearl Jam guitarist, Mike McCready made public his 20-year
battle with Crohn's disease and ulcerative colitis and has since been
committed to raising awareness about the disease, which can cause abdominal
pain, fever and weight loss that can disrupt peoples' lives. The benefit
concert will take this subject, typically thought to be too delicate to
discuss in public, out of the shadows and into the spotlight. McCready has
been a spokesperson for the NW Chapter of CCFA and is also featured in a
radio Public Service Announcement (PSA) released in January for the group.
The concert will benefit CCFA's search for a cure.
"Having struggled with Crohn's disease for more than 20 years and
experienced first hand difficulties in getting a diagnosis and treatment, I
want to help others learn about the disease, how it is affecting them and
how to find ways to cope," said McCready.
Approximately 500,000 people in the U.S. have CD. However, people with
CD are reticent to talk about their symptoms to healthcare providers, and
therefore, often suffer for many years without a diagnosis or treatment.
The consequence of not receiving medical care can be progression of the
disease leading to surgical removal of affected parts of the digestive
system. Although there is no cure for the disease, patients can currently
get treatments to reduce symptoms and guidance on how to manage them in
their daily lives. Those suffering from severe CD even go so far as to
"bathroom map" -- scouting bathrooms in advance of basic outings to the
grocery store, mall, or social activities because they never know when a
severe attack will strike. This is not always easy when working or trying
to lead a normal life. People report that CD has affected their emotional
well-being and disrupted their educational pursuits, jobs and personal
www.CrohnsandMe.com has just been launched to help patients understand
their disease and manage the symptoms effectively. "At UCB we have a deep
commitment to helping patients break through the limitations that diseases
like CD impose on people and enjoy life more," said David Robinson, Vice
President, Immunology Business Unit at UCB. "We created www.CrohnsandMe.com
and became a sponsor of the Pearl Jam benefit concert to help CD patients
achieve this goal."
The interactive Web site provides guidance and support to patients and
contains a wealth of information about CD. It encourages CD patients to
step back into the world and shows them the way. Advice is available on
handling CD symptoms in the workplace, while traveling and when dining out
as well as how to minimize flare-ups. The site also features real stories
of CD patients successfully managing their symptoms and taking control of
their lives. People with CD can join the patient community on
www.CrohnsandMe.com to gain access to more information.
The Pearl Jam benefit concert will be held Thursday, July 20th at 8
p.m. at Portland's Arlene Schnitzer Concert Hall. Comedian David Cross and
other special guests will be on hand for an evening of comedy and music to
support CCFA. Tickets are available at all Ticketmaster outlets, online at
CCFA.org, or by phone at 503-224-4400.
In an effort to provide people with Crohn's disease with disease
management information and resources designed expressly with their needs in
mind, UCB has launched CrohnsandMe.com -- a dynamic Web site focused on
helping people thoroughly understand Crohn's disease and live with it every
UCB (www.ucb-group.com) is a leading global biopharmaceutical company
dedicated to the research, development and commercialization of innovative
pharmaceutical and biotechnology products in the fields of central nervous
system disorders, allergy/respiratory diseases, immune and inflammatory
disorders and oncology -- UCB focuses on securing a leading position in
severe disease categories. Employing over 8,500 people in over 40
countries, UCB achieved revenues of euro 2.3 billion in 2005. UCB is listed
on the Euronext Brussels Exchange with a market capitalization of
approximately euro 6.0 billion. Worldwide headquarters are located in
Brussels, Belgium, and U.S. headquarters are located in Atlanta, Georgia.
SOURCE UCB, Inc.